Article
Food Science & Technology
Andreas A. A. Argyriou, Emmanouil V. V. Dermitzakis, Georgia Xiromerisiou, Michail Vikelis
Summary: This study aimed to evaluate the effectiveness of combining dual therapy with BTX and anti-CGRP MAbs in treatment-refractory CM patients. Retrospective review of medical files of 19 patients showed that dual therapy was effective and associated with significant clinical improvement in the majority of cases, with favorable safety and tolerability.
Review
Clinical Neurology
Sheena Pillai, Niushen Zhang
Summary: A comprehensive headache treatment plan usually includes both medication and non-medication strategies. Manual therapies, including myofascial trigger point injections, myofascial release, massage, strain counterstrain technique, ischemic compression, and spinal manipulative therapies, have shown potential benefit in treating various types of headaches. Although more studies are needed, recent findings suggest that manual therapies could be an important tool for treating some headache disorders.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
(2023)
Review
Pharmacology & Pharmacy
Min Young Kim, Daniel C. Brennan
Summary: Significant progress has been made in the pathophysiology, diagnosis, and treatment of antibody-mediated rejection (ABMR) in recent decades, but effective treatment for chronic ABMR remains a challenge. Chronic ABMR has a distinct phenotype from active ABMR and is mainly caused by de novo donor specific antibodies (DSA), leading to progressive graft injury.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Gastroenterology & Hepatology
Sheikh Mohammad Fazle Akbar, Osamu Yoshida, Yoichi Hiasa
Summary: Patients with chronic hepatitis B (CHB) are a long-term reservoir of hepatitis B virus (HBV). If not properly treated, these CHB patients may develop serious complications. Current antiviral drugs for CHB treatment cannot eradicate all forms of HBV and cannot stop the progression of complications for most patients. Therefore, there is an urgent need for the development of new therapies for CHB. Immune dysregulation may be responsible for HBV persistence and liver damage in CHB. Despite 30 years of immune therapies for CHB, an effective regimen of immune therapy is yet to be realized. This review discusses the pros and cons of different immune therapies for CHB patients in the past 30 years to provide insights for the development of an evidence-based, effective, and patient-friendly immune therapy regimen for CHB treatment.
JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Medicine, Research & Experimental
Linda Harris, Tom O'Connell, Jonathan J. Woolley, Gilbert L'Italien, Tamela Martin, Vladimir Coric, James A. Moren
Summary: The aim of this study is to assess the variations in medication costs among patients using calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for migraine prevention, based on the number of monthly migraine days (MMD). The results showed that medication costs increased significantly with an increase in the number of monthly migraine days.
ADVANCES IN THERAPY
(2023)
Article
Clinical Neurology
Zifan Zhou, Robert Urman, Karminder Gill, Andrew S. Park, Fiston Vuvu, Leah B. Patel, Jingsong Lu, Rolin L. Wade, Lindsay Frerichs, Mark E. Bensink
Summary: Most patients initiating nAMSMs had prior treatment with acute and preventive medications. Approximately one-third of patients had prior treatment with anti-CGRP pathway mAbs. After starting nAMSMs, more than one-third of patients discontinued at least one traditional acute medication and one-third of patients discontinued at least one traditional preventive medication. Despite nAMSM initiation, most patients with prior anti-CGRP pathway mAb use continued mAb use. Around 15% of patients without a prior mAb newly started a mAb. These results provide insight into how nAMSMs and mAbs have been integrated into clinical management of migraine in the real-world.
JOURNAL OF HEADACHE AND PAIN
(2023)
Review
Gastroenterology & Hepatology
Maura A. Morrison, Florent Artru, Francesca M. Trovato, Evangelos Triantafyllou, Mark J. McPhail
Summary: Acute-on-chronic liver failure (ACLF) is a syndrome that occurs in approximately 30% of hospitalized cirrhosis patients, characterized by acute decompensation of liver function, extra-hepatic organ failures, and high short-term mortality. Currently, no specific therapies are available for ACLF, and management is limited to addressing the underlying cause and supporting organ function. Due to the high prevalence and mortality of this severe liver disease, targeted treatments are urgently needed. Increasing evidence suggests that systemic inflammation and immune dysfunction play an important role in the pathophysiology of ACLF, leading to the emergence of new therapeutic targets. This review aims to provide an overview of ongoing studies on potentially promising therapies and their potential utilization in managing ACLF.
LIVER INTERNATIONAL
(2023)
Review
Medicine, General & Internal
Enrico Ammirati, Emanuele Bizzi, Giacomo Veronese, Matthieu Groh, Caroline M. Van de Heyning, Jukka Lehtonen, Marc Pineton de Chambrun, Alberto Cereda, Chiara Picchi, Lucia Trotta, Javid J. Moslehi, Antonio Brucato
Summary: The field of cardio-immunology is rapidly evolving due to the use of non-invasive diagnostic tools and immunomodulating therapies. Recent data suggest the effectiveness of these therapies in autoimmune disorders, isolated forms of myocarditis, and severe cases of COVID-19. Ongoing clinical trials are also evaluating the use of specific medications in the treatment of acute myocarditis and recurrent pericarditis. The interaction between the cardiac and immune systems is being studied using new research models introduced by immune-mediated therapies in oncology.
FRONTIERS IN MEDICINE
(2022)
Article
Clinical Neurology
Benjamin W. Friedman, Eddie Irizarry, Darnell Cain, Arianna Caradonna, Mia T. Minen, Clemencia Solorzano, Eleftheria Zias, David Zybert, Michael McGregor, Polly E. Bijur, E. John Gallagher
Summary: The study found that IV metoclopramide and diphenhydramine combination was more effective than placebo in treating acute moderate or severe posttraumatic headache in the emergency room, with comparable safety profiles.
Article
Clinical Neurology
Benjamin W. Friedman, Eddie Irizarry, Darnell Cain, Arianna Caradonna, Mia T. Minen, Clemencia Solorzano, Eleftheria Zias, David Zybert, Michael Mcgregor, Polly E. Bijur, E. John Gallagher
Summary: The study demonstrated that IV metoclopramide and diphenhydramine were more effective than placebo for acute posttraumatic headache in the emergency room, showing improvement in pain scale scores, although metoclopramide was associated with slightly higher incidence of adverse events.
Article
Chemistry, Medicinal
Christopher C. Anderson, Juliana H. VanderPluym
Summary: Migraine is a common neurological disorder and its pathophysiology is a major focus of research. Lasmiditan, a first-in-class 5-HT1F receptor agonist, has been developed as a treatment for migraine attacks. This article reviews the design, development, and place in therapy for lasmiditan, as well as its efficacy and safety compared to other acute treatments.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Review
Oncology
A. Bazinet, H. M. Kantarjian
Summary: Acute myeloid leukemia (AML) is a genetically heterogeneous disease. Personalized therapy based on patient characteristics and cytogenetic/molecular features is now possible. Intensive or low-intensity treatment approaches can be selected based on patient age and/or comorbidities. Molecularly defined AML subtypes benefit from targeted agents, while novel therapies are needed for TP53-mutated AML. Optimization of AML therapy in patients without actionable mutations and the role of measurable residual disease in modifying therapy are also discussed.
ANNALS OF ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Francesca R. Buccellato, Marianna DAnca, Gianluca Martino Tartaglia, Massimo Del Fabbro, Elio Scarpini, Daniela Galimberti
Summary: Alzheimer's disease is a major cause of dementia in elderly people, and currently there is no final cure. Treatment strategies aim to alleviate symptoms, but recently there have been breakthroughs in disease-modifying therapies. Researchers are also seeking early detection and treatment methods through new biomarkers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Rahul S. S. Bhansali, Keith W. W. Pratz, Catherine Lai
Summary: Acute myeloid leukemia (AML), the most common acute leukemia in adults, has seen significant advancements in understanding its molecular profile and treatment options in the past decade. The classification of AML subtypes has shifted from morphology to molecular and genetic basis, leading to improved outcomes with low-intensity induction therapy and targeted oral therapies. However, challenges remain in sequencing and combining therapies, as well as addressing poor prognosis in certain subtypes like TP53 mutations. This review discusses recent updates in AML classification, low-intensity and novel oral combination therapies, and ongoing translational advances for high-risk disease subtypes.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Chemistry, Medicinal
Muhammad Umer, Dinesh K. K. Kalra
Summary: Fabry disease is a rare genetic disorder that affects the metabolism of glycosphingolipids. It results in the accumulation of globotriaosylceramide in lysosomes due to a deficiency of the alpha-galactosidase A enzyme. This disease affects multiple organs, mainly the kidneys, heart, and cerebrovascular system. Early diagnosis and treatment are crucial in preventing irreversible tissue damage, organ failure, and life-threatening complications that can significantly impact life expectancy. This review focuses on the current and emerging treatment options for Fabry disease.